Mabwell to present clinical results of B7-H3-ADC 7MW3711 at 2025 ESMO Congress for advanced solid tumors.

Unusual Whales
2025.10.14 16:07
In Shanghai on October 14, 2025, Mabwell (688062.SH), a comprehensive biopharmaceutical firm, reported that the clinical trial findings of its new B7-H3-targeting ADC (Research & Development code: 7MW3711) for numerous advanced solid tumors will be showcased in a poster presentation.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.